Decibel Therapeutics to Provide Corporate Update at Jefferies Gene Therapy Summit

Steven Holtzman, president and chief executive officer of Decibel, will discuss Decibel’s comprehensive approach to the discovery and development of medicines for hearing and balance. “Gene therapy will be a critical therapeutic modality for addressing hearing and balance, not only for rare, monogenic congenital deafness, but also for more prevalent disorders,” said Holtzman. “Our approach is based on our deep understanding of hearing biology. This has provided proprietary insights into the best combinations of AAV vectors and genetic regulatory sequences to achieve high levels of gene expression in targeted cell types while maintaining exquisite cell type selectivity, minimizing off-target effects.”

Initial programs in Decibel’s gene therapy pipeline include DB-XX2 for congenital, profound deafness resulting from otoferlin (OTOF) deficiency, and DB-XX1, which aims to tackle both age-related balance disorders and bilateral vestibular hypofunction. Decibel recently launched a Phase 1b safety and efficacy study for its lead program, DB-020, a small molecule therapy designed to prevent ototoxicity induced by the cancer therapy cisplatin.

About Decibel Therapeutics, Inc.

Decibel Therapeutics, a clinical-stage biotechnology company, has established the world’s first comprehensive drug discovery, development and translational research platform for hearing and balance disorders. Decibel’s lead therapeutic candidate, DB-020, is being investigated for the prevention of ototoxicity associated with cisplatin chemotherapy. Decibel is also advancing a portfolio of discovery-stage programs aimed at restoring hearing and balance function to further our vision of a world in which the benefits and joys of hearing are available to all. Decibel is headquartered in Boston, Mass. For more information about Decibel Therapeutics, please visit www.decibeltx.com or follow @DecibelTx on Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005152/en/